Elsevier

Vaccine

Volume 24, Issue 16, 12 April 2006, Pages 3191-3202
Vaccine

Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses

https://doi.org/10.1016/j.vaccine.2006.01.032Get rights and content

Abstract

Cytoplasmic delivery of proteins or CTL epitopes is crucial for the presentation of antigen for the generation of CTL. We previously described the use of the 16-amino acid peptide penetratin from the Drosophila Antennapedia domain (Int) to transport CTL epitopes into cells. Here we show that, Int, incorporating MUC1 CTL epitopes in tandem is able to facilitate their rapid uptake by macrophages and dendritic cells (DC) in an energy-dependent endocytic pathway. We also demonstrate for the first time that Int conjugated proteins are also able to be efficiently taken up by DC. Furthermore, C57BL/6 and HLA-A2 transgenic mice immunized with the Int-peptides or Int-proteins induce strong IFN-γ secreting T cells and weak IgG1 antibodies. Immunized C57BL/6 mice were protected against the growth of a MUC1+ tumor cell line.

Introduction

The delivery of immunogens to antigen presenting cells and their subsequent uptake into the cells, processing and presentation by the MHC class I and/or II molecules is crucial for the development of vaccines. Peptide or protein based vaccines without a mechanism of delivery into antigen presenting cells have limited uptake. To overcome this problem, methods such as targeting cell surface receptors or the use of membrane translocating peptides to deliver proteins into the cytoplasm of cells, including, antigen presenting cells have been investigated [1].

Penetratin provides a unique approach for the transport of peptides and proteins into the cytoplasm of cells. The TAT protein from human immunodeficiency virus, the VP22 protein from herpes simplex virus and Pep-1, an amphipathic peptide have been shown to deliver peptides and proteins into cells [2], [3], [4], [5], [6], [7], [8], [9], [10], [11]. The 60-mer DNA binding domain (homeodomain) of the Drosophila transcription factor Antennapedia, consists of 3 α-helices, the region responsible for internalization having been mapped to a 16-amino acid peptide, RQIKIWFQNRRMKWKK (penetratin or Int) within the third helix [12]. A recombinant fusion protein consisting of the 60-amino acid homeodomain fused to an influenza nucleoprotein cytotoxic T cell (CTL) peptide generated CTLs to the peptide, however SDS was required to denature the antigen [13], [14]. We had previously demonstrated that the 16-mer Int-peptide linked in tandem with the H-2Kb CTL epitope of ovalbumin, SIINFEKL (RQIKIWFQNRRMKWKK-SIINFEKL; IntSIINFEKL), was rapidly internalized by cells [15]. Injection with IntSIINFEKL resulted in targeting the MHC class I pathway, the induction of CTL and immunity against E.G7-OVA tumor cells [15]. It is important to note that in these studies there was no requirement for the addition of denaturing agents or adjuvants.

Studies on the uptake mechanism of peptides such as penetratin and Tat has indicated that these peptides are transported into cells by a receptor-dependent mechanism [16], [17], [18]. In contrast to earlier studies indicating receptor and energy-independent uptake, new studies have shown that penetratin and Tat are internalized via negative-charged receptors [17], [19]. However, the mechanism of uptake is more complex dependent on the peptides used (e.g. penetratin, Tat), the peptide cargo (e.g. peptide, protein) and different cell types used for assessing uptake [17], [20], [21], [22].

Our laboratory has been interested in receptor-mediated uptake of antigens to induce CTL specific to tumor associated antigens such as MUC1 which is over-expressed on epithelial tumors of breast, colon, ovary [23], [24], [25]. We have identified CTL epitopes of 5 H-2 alleles (H-2Kb, H-2Db, H-2Kd, H-2Dd, H-2Kk) and to HLA-A2 within the variable number of tandem repeat (VNTR) region after conjugation of MUC1 fusion protein (containing 5 VNTR repeats) to oxidized mannan [26], [27], [28], [29], [30], [31]. In addition, we have identified CTL epitopes to H-2d, H-2b and to HLA-A2 which are outside the VNTR region [32]. We have demonstrated that immunization of mice with MUC1 GST fusion protein or MUC1 peptides (from VNTR and non-VNTR region) generated high antibody responses with no cellular immunity [23], [24], [25], [33], [34], [35], [36], [37]. Peptides or fusion proteins alone, without the use of in vivo grown dendritic cells (DC) or adjuvants do not efficiently induce CTL responses and tumor protection. To induce cellular immune responses (CTL, CD8+ T cells), MUC1 fusion protein was conjugated to oxidized mannan and required 3 injections in mice [1], [28], [29], [31], [33], [36], [37], [38], [39], [40], [41]. DC pulsed with MUC1 peptides or MUC1 coupled to mannan was required to induce cellular responses after 3 injections [26], [27], [28], [29], [33], [37]. In this study we linked these MUC1 GST fusion proteins [N-terminus (region 33–103) and VNTR (comprising 5 repeats)] and MUC1 CTL epitopes from both the VNTR and non-VNTR regions to Int, to induce IFN-γ secreting T cells in both C57BL/6 and HLA-A2 transgenic mice. Furthermore, C57BL/6 mice immunized once with these proteins showed protection against a MUC1+ tumor challenge. It is demonstrated for the first time that Int conjugated to proteins is able to generate effective T cell responses. The Int-peptide/protein combination is a very powerful method of inducing CTLs and tumor immunity.

Section snippets

Peptide and proteins

Peptides (Table 1) were synthesized at the Austin Research Institute and the purity of the peptides (>95%) was determined by mass spectrometry. MUC1FP, a GST fusion protein comprising of 5 VNTR repeats [35] and NFP, a GST fusion protein from the N-terminus (extracellular region, 33–103) of MUC1 were produced using the bacterial vectors PGEX-3X and PGEX-2T, respectively. An alternative source of the MUC1FP antigen, not containing GST, was prepared to assay VNTR specific immune responses in

Immunofluoresence

The internalization of proteins (IntMUC1FP and IntNFP) and Int-MUC1 peptide (IntMUC1Kb) in peritoneal macrophages was examined by immunofluoresence. Cells incubated with IntMUC1FP, IntMUC1Kb and IntNFP (Fig. 1A, C, E) showed increased internalization (higher % of cells positive and higher fluorescence intensity, >90% cells) compared to cells that were incubated with MUC1FP, MUC1Kb or NFP (Fig. 1B, D, F) (<10% cells). IntMUC1Kb peptide demonstrating intracellular staining (Fig. 1I); similar

Discussion

To generate effector T cells to exogenous antigens, they must be processed in the cytoplasm of antigen presenting cells (primarily DCs) and presented to CD8 T cells in the context of MHC class I molecules [1]. Exogenous antigens are usually processed in late endosomes/lysosomes and presented by MHC class II molecules to CD4 cells [50]. DC in particular are capable of processing antigens and peptides for presentation by class I molecules via the cross presentation pathway. A number of approaches

Acknowledgements

This work was supported by the National Breast Cancer Foundation Kathleen Cunningham project grant (V.A., G.P., B.L., I.F.C.M.), NH&MRC project grant 223310 (V.A.), Susan Komen Breast Cancer Foundation grant (G.P.), Equity Trustees of Australia (V.A.) and State Trustees of Australia Foundation (V.A.). V.A. is an NH&MRC R. Douglas Wright Fellow 223316, B.L. is an NH&MRC Senior Research Fellow and R.A. and J.P.V. were supported by Vrje University Medical Center, The Netherlands. All authors were

References (62)

  • G.A. Pietersz et al.

    Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1

    Vaccine

    (2000)
  • V. Apostolopoulos et al.

    The immunogenicity of MUC1 peptides and fusion protein

    Cancer Lett

    (1995)
  • S.A. Lofthouse et al.

    Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen

    Vaccine

    (1997)
  • V. Apostolopoulos et al.

    Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses

    Vaccine

    (2000)
  • V. Apostolopoulos et al.

    Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

    Vaccine

    (1996)
  • P. Brossart et al.

    Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies

    Blood

    (1999)
  • J.W. Yewdell et al.

    Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines

    Adv Immunol

    (1999)
  • I.F. McKenzie et al.

    Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses

    Vet Immunol Immunopathol

    (1998)
  • M.P. Schutze-Redelmeier et al.

    Antennapedia transduction sequence promotes anti tumour immunity to epicutaneously administered CTL epitopes

    Vaccine

    (2004)
  • D. Derossi et al.

    Cell internalization of the third helix of the Antennapedia homeodomain is receptor- independent

    J Biol Chem

    (1996)
  • I.A. Ignatovich et al.

    Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways

    J Biol Chem

    (2003)
  • G. Drin et al.

    Studies on the internalization mechanism of cationic cell-penetrating peptides

    J Biol Chem

    (2003)
  • C.D. Partidos et al.

    Priming of measles virus-specific CTL responses after immunization with a CTL epitope linked to a fusogenic peptide

    Virology

    (1996)
  • G.A. Pietersz et al.

    Generation of cellular immune responses to antigenic tumor peptides

    Cell Mol Life Sci

    (2000)
  • S. Fawell et al.

    Tat-mediated delivery of heterologous proteins into cells

    Proc Natl Acad Sci USA

    (1994)
  • A.D. Frankel et al.

    Tat protein from human immunodeficiency virus forms a metal-linked dimer

    Science

    (1988)
  • D.A. Mann et al.

    Endocytosis and targeting of exogenous HIV-1 Tat protein

    EMBO J

    (1991)
  • A. Martin et al.

    Herpes simplex virus tegument protein VP22 contains overlapping domains for cytoplasmic localization, microtubule interaction, and chromatin binding

    J Virol

    (2002)
  • G. Elliott et al.

    Intercellular trafficking of VP22-GFP fusion proteins

    Gene Ther

    (1999)
  • A. Phelan et al.

    Intercellular delivery of functional p53 by the herpesvirus protein VP22

    Nat Biotechnol

    (1998)
  • M.C. Morris et al.

    A peptide carrier for the delivery of biologically active proteins into mammalian cells

    Nat Biotechnol

    (2001)
  • Cited by (30)

    • Generated SecPen_NY-ESO-1_ubiquitin-pulsed dendritic cell cancer vaccine elicits stronger and specific T cell immune responses

      2021, Acta Pharmaceutica Sinica B
      Citation Excerpt :

      We fused a SecPen sequence in the N-terminal of NY-ESO-1 protein, which would make NY-ESO-1 endogenization. CPPs were used in DC vaccines for many years and proved to be efficient in inducing both CD4+ and CD8+ T cell immune responses25,52,53. And SecPen was investigated and showed a stronger ability of membrane permeability than other CPPs such as R8 and Tat54.

    • Enhancing antitumor immune responses by optimized combinations of cell-penetrating peptide-based vaccines and adjuvants

      2016, Molecular Therapy
      Citation Excerpt :

      Previous reports showed the capacity of CPP to induce TAA-specific CD8 T cell immune responses using DCs transduced with TAT-Trp228 or TAT-carcinoembryonic antigen fusion protein (TAT-CEA) injected with CpG oligodeoxynucleotides or Poly(I:C) as adjuvant.29,30 Vaccination with penetratin CPP conjugated to mucin 1 (MUC1) epitopes also showed tumor-specific immune responses elicited by CPP.31 All these data are encouraging for the promotion of TAA-specific immune responses by CPP vectors.

    • Cell-penetrating peptide-mediated subunit vaccine generates a potent immune response and protection against Streptococcus iniae in Japanese flounder (Paralichthys olivaceus)

      2015, Veterinary Immunology and Immunopathology
      Citation Excerpt :

      The efficiency of antigen capture, processing, and presentation by antigen-presenting cells (APCs) is pivotal for inducing an effective immune response (Mittendorf et al., 2007). Cell-penetrating peptide (CPP)-cargo conjugates have been reported can be transported into the cytoplasm of APCs, through the MHC class I pathway to induce strong CTL responses (Wadia et al., 2004; Foerg and Merkle, 2008), and leads to the generation of potent immune responses (Brooks et al., 2010a,b; Apostolopoulos et al., 2006). CPPs, which are also called protein transduction domains, usually consist of no more than 30 amino acids with net positive charge (Schwarze and Dowdy, 2000).

    • Cell-penetrating peptides mediated protein cross-membrane delivery and its use in bacterial vector vaccine

      2014, Fish and Shellfish Immunology
      Citation Excerpt :

      The cellular entry mechanisms of CPPs are categorized into two groups: energy-dependent endocytosis and energy-independent direct translocation across the membrane bilayer [9,10]. There is now a wealth of evidence demonstrating the superior cellular delivery of cargos through conjugation to CPPs, ultimately leading to the generation of potent immune responses [11–14]. Therefore, CPP could offer significant potential to enhance antigen uptake by APCs and thus could be used in the design and development of bacterial vector vaccine.

    View all citing articles on Scopus
    1

    These authors contributed equally to this work.

    2

    Present address: Vrije Universiteit, Faculteit der Geneeskunde, Van der Boechorststraat 7, 1081 Amsterdam, The Netherlands.

    View full text